Background: This study evaluated the antitumor efficacy and safety of a novel
oxaliplatin/raltitrexed combination in pretreated advanced colorectal cancer patients …

We review the pharmacology and clinical administration of the commonly used platinum-
based anticancer drugs cisplatin and carboplatin, and the more recently approved …

Background This multicenter, phase II, open-label study evaluated the antitumor efficacy and
safety of oxaliplatin and raltitrexed (Tomudex) in non-pretreated advanced colorectal cancer …

Background To evaluate the safety and efficacy of the novel raltitrexed/oxaliplatin
combination (TOMOX) as first-line chemotherapy for patients with advanced colorectal …

The choice between cisplatin (cis) and carboplatin (carbo) as the platinum analogue to be
used in combination chemotherapy regimens continues to be a point of controversy, and a …

Background To evaluate the efficacy and safety of the combination of oxaliplatin and S-1
(OS) in treating metastatic colorectal cancer. Patients and methods Eligible patients were …

Background Oxaliplatin represents a main component of cytotoxic treatment regimens in
colorectal cancer (CRC). Given its efficacy, oxaliplatin is frequently re-administered in the …

Purpose In the OPTIMOX1 trial, previously untreated patients with advanced colorectal
cancer were randomly assigned to two different schedules of leucovorin, fluorouracil, and …

Oxaliplatin is a third-generation platinum compound approved for clinical use relatively
recently as compared to other drugs of the same class. Its main cellular target is DNA, where …

Simple Summary The efficacy and safety of oxaliplatin-based regimens in late-care settings
have been poorly reported. In 119 mCRC patients, the oxaliplatin retreatment response rate …